Prostate cancer physician and biotechnology entrepreneur
Knownfor
Co-discoverer of P2PSA, a key component of the Prostate Health Index test (phi test) and founder of Bellicum Pharmaceuticals, Inc.
Kevin M. Slawin (born 1961) is an American physician and the founder of Bellicum Pharmaceuticals and the Vanguard Urologic Institute at Memorial Hermann Medical Group. He was also the Director of Urology at Memorial Hermann Hospital. Slawin specializes in the diagnosis and treatment of urologic cancers and robotic surgery. He is also possesses patents related to the advancement of prostate cancer diagnosis, staging and treatment[1] and to the cellular immunotherapy of cancer.
Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994,[5] and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, after the well known Houston philanthropist. In 2007, he left the full-time faculty of Baylor to found The Vanguard Urologic Institute, that works on advancing treatment of urologic diseases. Slawin is a pioneer in the development of Robotic-Assisted Laparoscopic Prostatectomy.[6]
Slawin is a co-discoverer of -2proPSA (P2PSA),[8][9] a molecular form of prostate specific antigen, which has been shown to improve the accuracy of prostate cancer screening.[10] A multi-center study supported by the National Cancer Institute verified the ability of proPSA to be a valid marker for early detection of prostate cancer.[11] The -2proPSA, along with free and total PSA, are measured in a new molecular test called the prostate health index (phi) (Beckman Coulter, Inc.) that was FDA-approved in 2012[12] is now widely available.[13]
Slawin is co-discoverer of the novel, clipped form of benign PSA, which he named "BPSA".[9]
Slawin is a co-inventor with David Spencer, PhD, of inducible CD40 (iCD40), a re-engineered dendritic cell receptor protein which allows for the in-vivo activation of the immune system in a specific, controlled manner.[14][15]
Slawin is co-inventor of a number of novel technologies related to the enhancement and control of adoptive T cell therapy for cancer and other serious diseases.[16]
Bellicum Pharmaceuticals, Inc.
Slawin founded Bellicum Pharmaceuticals, Inc.[17] in 2004. He served as Executive Chairman and Chief Medical Officer until 2014. On December 18, 2014, Bellicum completed a successful IPO on the NASDAQ (Nasdaq:BLCM). In 2015, Dr. Slawin transitioned to the roles of Chief Technology Officer, member of the Board of Directors, and a significant shareholder.[18][19] In 2016, Slawin transitioned out of an operational role at the company. In 2017, Slawin resigned from the Board of Directors.
↑ Mikolajczyk, Stephen; Millar, L. S.; Wang, T. J.; Rittenhouse, H. G.; Marks, L. S.; Song, W; Wheeler, T. M.; Slawin, K. M. (2000). "A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue". Cancer Research. 60 (3): 756–759. PMID10676664.
↑ Hanks, Brent A.; Jiang, Jianghong; Singh, Rana A K.; Song, Weitao; Barry, Michael; Huls, Mary H.; Slawin, Kevin M.; Spencer, David M. (2005). "Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo". Nature Medicine. 11 (2): 130–137. doi:10.1038/nm1183. PMID15665830. S2CID33397197.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.